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Skeletal muscle atrophy is a common and debili-
tating condition that lacks a pharmacologic therapy.
To develop a potential therapy, we identified 63
mRNAs that were regulated by fasting in both human
and mouse muscle, and 29 mRNAs that were regu-
lated by both fasting and spinal cord injury in human
muscle. We used these two unbiased mRNA expres-
sion signatures of muscle atrophy to query the
Connectivity Map, which singled out ursolic acid as
a compound whose signature was opposite to those
of atrophy-inducing stresses. A natural compound
enriched in apples, ursolic acid reduced muscle
atrophy and stimulated muscle hypertrophy in
mice. It did so by enhancing skeletal muscle
insulin/IGF-I signaling and inhibiting atrophy-associ-
ated skeletal muscle mRNA expression. Importantly,
ursolic acid’s effects on muscle were accompanied
by reductions in adiposity, fasting blood glucose,
and plasma cholesterol and triglycerides. These find-
ings identify a potential therapy for muscle atrophy
and perhaps other metabolic diseases.
INTRODUCTION
Skeletal muscle atrophy is characteristic of starvation and
a common consequence of aging. It also complicates a wide
range of severe human illnesses, including diabetes, cancer,
chronic renal failure, congestive heart failure, chronic respiratory
disease, acute critical illness, chronic infections such as HIV/
AIDS, spinal cord injury (SCI), muscle denervation, and many
other medical and surgical conditions that limit muscle use.
However, we currently lack medical therapies to prevent or
reverse skeletal muscle atrophy in humans. Sequelae of muscle
atrophy (includingweakness, falls, fractures, opportunistic respi-
ratory infections, and loss of independence) are thus common-
place in hospital wards and extended care facilities.CPrevious studies demonstrated that skeletal muscle atrophy is
driven by conserved changes in skeletal muscle gene expression
(Bodine et al., 2001a; Sandri et al., 2004). We therefore hypoth-
esized that pharmacologic compounds with opposite effects
on gene expression might inhibit skeletal muscle atrophy. To
test this, we first determined an mRNA expression signature of
one atrophy-inducing stress (fasting) in human and mouse
skeletal muscle. We then used these unbiased data in conjunc-
tion with the Connectivity Map (Lamb et al., 2006) to identify
candidate small molecule inhibitors of muscle atrophy. This
approach identified a natural compound that may have applica-
tions in the treatment of human skeletal muscle atrophy.RESULTS
Effects of Fasting on Skeletal Muscle mRNA Expression
in Humans
Prolonged fasting induces muscle atrophy, but its effects on
global mRNA expression in human skeletal muscle are not
known. To determine this, we studied seven healthy adult
humans (three male and four female) with ages ranging from 25
to 69 years (mean = 46 years). The mean body mass index of
these subjects (±SEM) was 25 ± 1. Their mean weight was
69.4 ± 4.8 kg. Baseline circulating levels of hemoglobin A1c
(HbA1c), triglycerides (TGs), thyroid-stimulating hormone (TSH),
free thyroxine (free T4), C-reactive protein (CRP), and tumor
necrosis factor-a (TNF-a) were within normal limits (Figure 1A).
While staying in our Clinical Research Unit (CRU), the subjects
fasted for 40 hr by forgoing food but not water. The mean
weight loss during the fast was 1.7 ± 0.1 kg (3% ± 0% of the
initial body weight). After the 40 hr fast, we obtained a biopsy
from the subjects’ vastus lateralis (VL) muscle. Immediately
after the muscle biopsy, the subjects ate a mixed meal. Five
hours later (6 hr after the first biopsy), we obtained a second
muscle biopsy from their contralateral VL muscle. Thus, each
subject had amuscle biopsy under fasting and nonfasting condi-
tions. As expected, plasma glucose and insulin levels were low at
the end of the 40 hr fast, rose after the meal, and returned to
baseline by the time of the second biopsy (Figure 1A). These
data indicate comparable levels of plasma glucose and insulinell Metabolism 13, 627–638, June 8, 2011 ª2011 Elsevier Inc. 627
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Figure 1. Effect of Fasting on Skeletal Muscle mRNA Expression in Healthy Human Adults
(A) Study design. The table (insert) shows baseline circulating metabolic and inflammatory markers. The graph shows plasma glucose and insulin levels. Data are
means ± SEM from the seven study subjects. In some cases, the error bars are too small to see.
(B) Representative fasting-responsive human skeletal muscle mRNAs, and the effect of fasting on their log2 hybridization signals, as assessed by Affymetrix
Human Exon 1.0 ST arrays. In each subject, the fasting signal was normalized to the nonfasting signal from the same subject. Data are means ± SEM from seven
subjects. p% 0.02 by paired t test for all mRNAs shown. The complete set of 558 fasting-responsive mRNAs is shown in Table S1. See also Figure S1.
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Ursolic Acid Reduces Skeletal Muscle Atrophyat the times of the first (fasting) and second (nonfasting) muscle
biopsies.
To determine the effect of fasting on skeletal muscle mRNA
expression, we isolated RNA from the paired muscle biopsies
and then analyzed it with exon expression arrays. Using p %
0.02 (by paired t test) as criteria for statistical significance,
we found that 281 mRNAs were higher in the fasting state and
277 were lower (out of >17,000 mRNAs measured). A complete
list of these fasting-responsive mRNAs is shown in Table S1,
available online. Most of the mRNAs that were altered by fasting
did not have known roles in muscle atrophy. However, fasting
increased several mRNAs that encode proteins with known
roles in catabolic processes such as fat oxidation, reverse
cholesterol transport, thermogenesis, inhibition of protein
synthesis, autophagy, ubiquitin-mediated proteolysis, glutamine
transport, and heme catabolism (Figure 1B). Of these, atrogin-1,
MuRF1, and ZFAND5 mRNAs encode proteins known to be re-
quired for skeletal muscle atrophy in mice (Bodine et al., 2001a;
Hishiya et al., 2006). Conversely, fasting significantly decreased628 Cell Metabolism 13, 627–638, June 8, 2011 ª2011 Elsevier Inc.several mRNAs encoding proteins with known roles in anabolic
processes such as glycogen synthesis, lipid synthesis and
uptake, polyamine synthesis, iron uptake, angiogenesis, and
mitochondrial biogenesis (Figure 1B). Of these, PGC-1a mRNA
encodes a protein that inhibits atrophy-associated gene expres-
sion and skeletal muscle atrophy in mice (Sandri et al., 2006). We
used qPCR to validate several fasting-responsive mRNAs from
human skeletal muscle (Figure S1). Taken together, these data
established an mRNA expression signature of fasting in human
skeletal muscle.
Identification of Ursolic Acid as an Inhibitor
of Fasting-Induced Muscle Atrophy
The Connectivity Map describes the effects of >1300 bioactive
small molecules on global mRNA expression in several cultured
cell lines, and contains search algorithms that permit compari-
sons between compound-specific mRNA expression signatures
and mRNA expression signatures of interest (Lamb et al., 2006).
We hypothesized that querying the Connectivity Map with the
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Figure 2. Identification of Ursolic Acid as an Inhibitor of Fasting-Induced Skeletal Muscle Atrophy
(A) Fasting-regulated mRNAs common to human andmousemuscle that were used to query the Connectivity Map. Inclusion criteria were the following: p% 0.02
in fasted humanmuscle (by t test), p% 0.05 in fastedmousemuscle (by t test), and the existence of complimentary probes on HG-U133A arrays. (B) Connectivity
Map instances (or data sets), sorted by compound and cell line, with the most significant positive and negative correlations to the effect of fasting in human and
mouse muscle. The connectivity score, represented on the y axis, is a measure of the strength of the correlation (Lamb et al., 2006). p < 0.004 for all compounds
shown. (C, D, and F–H) Mice were administered metformin (250 mg/kg), ursolic acid (200 mg/kg), or an equivalent volume of vehicle alone via i.p. injection, and
then fasted. After 12 hr of fasting, a second injection of metformin, ursolic acid, or vehicle was administered. After 24 hr of fasting, the blood glucose was
measured and muscles were harvested. (C and D) Effect of metformin (C) and ursolic acid (D) on fasting blood glucose. Data are means ± SEM from 16 mice. (E)
Effect of 24 hr fast (relative to ad libitum feeding) on wet weight of lower hindlimb skeletal muscle (bilateral tibialis anterior [TA], gastrocnemius, and soleus). (F and
G) Effect of metformin (F) and ursolic acid (G) on fasted lower hindlimb muscle weight. (H) Effect of ursolic acid on atrogin-1 and MuRF1 mRNA levels in the TA
muscles of fasted mice. The data are normalized to the levels in vehicle-treated mice, which were set at 1. (E–H) Each data point represents one mouse, and the
horizontal bars denote the means. (C–H) P values were determined using unpaired t tests. See also Table S2.
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Figure 3. Identification of Ursolic Acid as an Inhibitor of Denervation-Induced Skeletal Muscle Atrophy
(A) mRNAs altered by both fasting and SCI in humanmuscle that were used to query the Connectivity Map. Inclusion criteria were the following: p% 0.02 in fasted
human muscle (by t test), p% 0.05 in untrained, paralyzed muscle (by t test), and the existence of complimentary probes on HG-U133A arrays.
(B) Connectivity Map instances with the most significant positive and negative correlations to the effect of fasting and SCI in human muscle. p < 0.005 for all
compounds shown.
(C–E) On day 0, the left hindlimbs of C57BL/6 mice were denervated by transsecting the left sciatic nerve. Mice were then administered ursolic acid (200 mg / kg)
or an equivalent volume of vehicle alone (corn oil) via i.p. injection twice daily for 7 days. On day 7, muscles were harvested for analysis. (C) Weights of the left
(denervated) lower hindlimb muscles were normalized to weights of the right (innervated) lower hindlimb muscles from the same mouse. Each data point
represents one mouse, and horizontal bars denote the means. P value was determined using an unpaired t test. (D and E) Effect of ursolic acid on skeletal
muscle fiber diameter in denervated gastrocnemius (D) and TA (E) muscles. Data are from >2500 muscle fibers per condition; p < 0.0001 by unpaired t test. See
also Table S3.
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Ursolic Acid Reduces Skeletal Muscle AtrophymRNA expression signature of fasting would identify inhibitors of
atrophy-associated gene expression and, thus, potential inhibi-
tors of muscle atrophy. We also reasoned that increasing the
specificity of our query would enhance the output. To this end,
we determined an evolutionarily conserved mRNA expression
signature of fasting by comparing the effect of fasting on human
skeletal muscle to the effect of a 24 hr fast on mouse skeletal
muscle. Our mouse studies were described previously (Ebert
et al., 2010). Altogether, we identified 35 mRNAs that were in-
creased by fasting and 40mRNAs that were decreased by fasting
in both human andmouse skeletalmuscle (Table S2). Of these, 63
were represented on the HG-U133A arrays used in the Connec-630 Cell Metabolism 13, 627–638, June 8, 2011 ª2011 Elsevier Inc.tivity Map (Figure 2A). We used these mRNAs (31 increased by
fasting and 32 decreased by fasting) to query the Connectivity
Map for candidate small molecule inhibitors of muscle atrophy.
The left side of Figure 2B shows the ten Connectivity Map
instances (or data sets) with the most significant positive corre-
lations to the effect of fasting in skeletal muscle. Of these, six
involved wortmannin or LY-294002 (inhibitors of phosphoinosi-
tide 3-kinase [PI3K]) or rapamycin (an inhibitor of the mammalian
target of rapamycin complex 1 [mTORC1]). Since PI3K and
mTORC1 mediate effects of insulin and IGF-I, and since
insulin/IGF-I signaling inhibits muscle atrophy and atrophy-asso-
ciated changes in skeletal muscle mRNA expression (Bodine
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Figure 4. Ursolic Acid Induces Skeletal Muscle Hypertrophy
Micewere provided ad libitum access to either standard chow (control diet) or standard chow supplementedwith 0.27%ursolic acid (ursolic acid diet) for 5 weeks
before grip strength was measured and tissues were harvested.
(A–C) Effect of ursolic acid on lower hindlimbmuscle weight (A), quadriceps weight (B), and upper forelimbmuscle (triceps and biceps) weight (C). Each data point
represents one mouse, and horizontal bars denote the means.
(D) Effect of ursolic acid on skeletal muscle fiber size distribution. Each distribution represents measurements of >800 triceps muscle fibers from seven animals
(>100 measurements / animal); p < 0.0001.
(E) Effect of ursolic acid on peak grip strength, normalized to body weight. Each data point represents one mouse, and horizontal bars denote the means.
Nonnormalized grip strength data were 157 ± 9 g (control diet) and 181 ± 6 g (ursolic acid diet) (p = 0.04). See also Figure S2.
Cell Metabolism
Ursolic Acid Reduces Skeletal Muscle Atrophyet al., 2001b; Sandri et al., 2004), these results lent confidence
that the Connectivity Map might be used to identify potential
inhibitors of muscle atrophy.
The right side of Figure 2B shows the ten Connectivity Map
instances with the most significant negative correlations to the
effect of fasting in skeletal muscle. These compounds, whose
effects on cultured cell lines were opposite to the effect of fasting
on muscle, included metformin (an insulin-sensitizing agent
widely used to treat type 2 diabetes) as well as ursolic acid. Inter-
estingly, ursolic acid was the only compound identified by both
this query and a second, independent query for potential inhibi-
tors of muscle atrophy (described below). Thus, we chose to
focus further experiments on metformin and ursolic acid.
To test the hypothesis that metformin and ursolic acid might
reduce fasting-induced muscle atrophy, we administered each
compound, or vehicle alone, via i.p. injection to C57BL/6 mice.
We then fasted the mice, and after 12 hr of fasting, the mice
received a second dose of the compound or vehicle. AfterC24 hr of fasting, the mice were examined. Both metformin
(250 mg/kg) and ursolic acid (200 mg/kg) significantly reduced
fasting blood glucose (Figures 2C and 2D). We next examined
the effects of metformin and ursolic acid on fasting-induced
muscle atrophy. In the absence of metformin and ursolic acid,
fasting reduced muscle weight by 9% (Figure 2E). Although
metformin did not alter muscle weight in fasted mice (Figure 2F),
ursolic acid increased it by 7% ± 2% (Figure 2G). Moreover,
consistent with its predicted inhibitory effect on fasting-induced
gene expression, ursolic acid reduced fasting levels of atrogin-1
and MuRF1 mRNAs (Figure 2H). Thus, ursolic acid, but not
metformin, decreased fasting-induced muscle atrophy.
Ursolic Acid Reduces Denervation-Induced
Muscle Atrophy
We asked whether a different mRNA expression signature of
muscle atrophy might also identify ursolic acid. To test this, we
queried the Connectivity Map with human skeletal muscleell Metabolism 13, 627–638, June 8, 2011 ª2011 Elsevier Inc. 631
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Figure 5. Ursolic Acid Promotes Muscle Growth by Repressing Atrophic Gene Expression, Inducing Trophic Gene Expression, and
Enhancing Skeletal Muscle IGF-I Signaling
(A and B) Mice were provided ad libitum access to either standard chow (control diet) or standard chow supplemented with 0.27% ursolic acid (ursolic acid diet)
for 5 weeks before tissues were harvested. (A) Ursolic acid-induced changes in the log2 hybridization signals of skeletal muscle mRNAs, as assessed by
Affymetrix Mouse Exon 1.0 ST arrays. n = 4 arrays per diet; each array assessed gastrocnemius RNA pooled from two mice. Data were filtered for p% 0.005 by
unpaired t test and log2 hybridization signalR8. Table shows the top six mRNAs most induced or repressed by dietary ursolic acid. (B) Effect of ursolic acid on
IGF1, atrogin-1, and MuRF1 mRNA levels, as assessed by qPCR. Data are means ± SEM.
(C) Mice were provided ad libitum access to either standard chow (control diet) or standard chow supplemented with the indicated concentration of ursolic acid
for 7 weeks before plasma IGF-I levels were measured. Each data point represents one mouse, and horizontal bars denote the means. P values were determined
by one-way ANOVA with Dunnett’s post test.
(D and E) Mice were provided ad libitum access to either standard chow (control diet) or standard chow supplemented with 0.27%ursolic acid for 16 weeks. Total
protein extracts from quadriceps muscles were subjected to SDS-PAGE, followed by immunoblot analysis for phosphorylated and total Akt, as indicated.
(D) Representative immunoblot. (E) In each mouse, the level of phospho-Akt was normalized to the level of total Akt. These ratios were then normalized to the
average phospho-Akt/total Akt ratio from control mice. Data are means ± SEM from nine mice per diet. P value was determined by unpaired t test.
(F–K) Serum-starved C2C12 myotubes were treated in the absence or presence of ursolic acid (10 mM) and/or IGF-I (10 nM), as indicated. For studies of the IGF-I
receptor, cells were harvested 2 min later, and protein extracts were subjected to immunoprecipitation with anti-IGF-I receptor b antibody, followed by
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SCI. Our studies of the effects of SCI on human skeletal muscle
gene expression were described previously (Adams et al.,
2011). Altogether, we identified 18 mRNAs that were increased
by fasting and SCI, and 17 mRNAs that were decreased by fast-
ing and SCI (Table S3). Of these, 29 were represented on the
HG-U133A arrays used in the Connectivity Map (Figure 3A), but
only 10 were common to the 63mRNAs used in our first Connec-
tivity Map query (IGF-IR, NOX4, SUPT6H, MRPS15, PDE7B,
PGC-1a, TSPAN13, TTLL1, VEGFA, and ZNF280B). When we
queried the Connectivity Map with this second signature of
muscle atrophy, the results partially overlapped with the results
of our first search: both search strategies identified LY-294002,
wortmannin, and rapamycin as predicted mimics of atrophy-
inducing stress, and ursolic acid (but not metformin) as a pre-
dicted inhibitor (Figure 3B). Strikingly, ursolic acid was the only
predicted inhibitor identified by both search strategies (compare
Figures 2B and 3B).
Because our second strategy utilized data from SCI subjects,
we hypothesized that ursolic acid might reduce denervation-
induced muscle atrophy. To test this, we selectively denervated
the left hindlimb muscles of mice by transsecting the left sciatic
nerve. This allowed us to use the right hindlimb as an intrasubject
control. We then administered ursolic acid or vehicle twice daily
for the next 7 days, while the mice continued to have ad libitum
access to food. Seven days after denervation, we compared
the left (denervated) and right (innervated) hindlimb muscles in
both groups. Ursolic acid significantly decreased denervation-
induced muscle loss (Figure 3C). Histologically, this effect of
ursolic acid was reflected as an increase in the size of dener-
vated skeletal muscle fibers (Figures 3D and 3E). Thus, ursolic
acid reduced denervation-induced muscle atrophy.
Ursolic Acid Induces Skeletal Muscle Hypertrophy
The finding that ursolic acid reduced muscle atrophy led us to
hypothesize that it might promote muscle hypertrophy in the
absence of an atrophy-inducing stress. To test this, mice were
allowed ad libitum access to either control chow or chow con-
taining 0.27% ursolic acid for 5 weeks. Compared to mice on
the control diet, mice receiving ursolic acid possessed larger
skeletal muscles (Figures 4A–4C), larger skeletal muscle fibers
(Figure 4D), and increased grip strength (Figure 4E). Moreover,
dietary ursolic acid increased the specific force generated by
muscles ex vivo (Figure S2). These data provided morphological
and functional evidence that ursolic acid induced skeletal
muscle hypertrophy.
Ursolic Acid Induces Trophic Changes in Skeletal
Muscle Gene Expression
Our discovery process suggested that ursolic acid might alter
skeletal muscle gene expression. To test this hypothesis, weimmunoblot analysis with anti-phosphotyrosine or anti-IGF-I receptor b antibodie
cells were harvested 20 min after addition of ursolic acid and/or IGF-I, and im
antibodies specific for the phosphorylated or total proteins indicated. (F–H) Re
phosphorylation of Akt (F), S6K (G), and IGF-I receptor (H). (I) Quantification of the
Akt, and S6K. Levels in the presence of ursolic acid and IGF-I are normalized to le
dashed line. Data are means ± SEM fromR 3 experiments. (J and K) Ursolic acid
See also Table S4 and Figure S3.
Ctook an unbiased approach, using exon expression arrays to
analyze gastrocnemius muscle mRNA expression in mice that
had been fed diets lacking or containing ursolic acid for 5 weeks.
Using stringent criteria for ursolic acid-induced effects on mRNA
levels (p < 0.005), and disregarding mRNAs with low levels of
expression (log2 hybridization signal <8), we found that ursolic
acid decreased 18 mRNAs and increased 51 mRNAs (out
of >16,000 mRNAs analyzed; Table S4).
As discussed above, atrogin-1 and MuRF1 are transcription-
ally upregulated by atrophy-inducing stresses (Sacheck et al.,
2007; and Figure 1B), and they are required for muscle atrophy
(Bodine et al., 2001a). Moreover, in our studies of fasted mice,
we found that ursolic acid reduced atrogin-1 andMuRF1mRNAs
(Figure 2H). Consistent with that finding, the arrays indicated
that dietary ursolic acid reduced atrogin-1 mRNA, which was
the most highly repressed mRNA measured on the array
(Figure 5A). Although MuRF1 mRNA was not measured by the
arrays used in these experiments, qPCR analysis confirmed
that dietary ursolic acid repressed both atrogin-1 and MuRF1
mRNAs (Figure 5B).
Interestingly, one of the most highly upregulated muscle
mRNAs was IGF1 (Figures 5A and 5B), which encodes insulin-
like growth factor-I (IGF-I), a locally generated autocrine/para-
crine hormone. IGF1 mRNA is known to be transcriptionally
induced in hypertrophic muscle (Adams and Haddad, 1996;
Gentile et al., 2010; Hameed et al., 2004). In addition, increased
skeletal muscle IGF1 expression reduces denervation-induced
muscle atrophy (Shavlakadze et al., 2005) and stimulatesmuscle
hypertrophy (Barton-Davis et al., 1998; Musaro et al., 2001).
Moreover, by stimulating skeletal muscle insulin/IGF-I signaling,
IGF-I represses atrogin-1 andMuRF1mRNAs (Frost et al., 2009;
Sacheck et al., 2004) as well asDDIT4LmRNA (Frost et al., 2009;
Sacheck et al., 2004), which, after atrogin-1 mRNA, was the
second most highly repressed mRNA in muscle from ursolic
acid-treated mice (Figure 5A). Thus, 5 weeks of dietary ursolic
acid altered skeletal muscle gene expression in a manner known
to reduce atrophy and promote hypertrophy, and muscle-
specific IGF1 induction emerged as a likely contributing mecha-
nism in ursolic acid-induced muscle hypertrophy.
Of note, our exon expression arrays indicated that ursolic acid
increased levels of all measured IGF1 exons (exons 2-6; Fig-
ure S3). However, ursolic acid did not alter levels of mRNAs
encoding myostatin (which reduces muscle mass [Lee, 2004]),
or twist or myogenin (which are induced by IGF-I during develop-
ment [Dupont et al., 2001; Tureckova et al., 2001]). We also
measured the effect of ursolic acid on plasma IGF-I levels, which
primarily reflect growth hormone-mediated hepatic IGF-I
production (Yakar et al., 1999). Although diets containing 0.14%
or 0.27% ursolic acid increased muscle mass (described in
greater detail below; Figure 6A), neither increased plasma
IGF-I (Figure 5C). Moreover, ursolic acid did not alter the amounts to assess phospho- and total IGF-I receptor, respectively. For other studies,
munoblot analyses were performed using total cellular protein extracts and
presentative immunoblots showing effect of ursolic acid on IGF-I-mediated
effect of ursolic acid on IGF-I-dependent phosphorylation of the IGF-I receptor,
vels in the presence of IGF-I alone, which were set at 1 and are indicated by the
enhances IGF-I-mediated phosphorylation of ERK (J) and FoxO3a/FoxO1 (K).
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Figure 6. Ursolic Acid Reduces Adiposity
(A and B) Mice were provided ad libitum access to standard chow supplemented with the indicated concentration of ursolic acid for 7 weeks before tissues were
harvested for analysis. Data are means ± SEM from ten mice per diet. (A) Effects of ursolic acid on weights of skeletal muscle (quadriceps + triceps), epididymal
fat, retroperitoneal fat, and heart. P values (determined by one-way ANOVA with post test for linear trend) were < 0.001 for muscle; 0.01 and 0.04 for epididymal
and retroperitoneal fat, respectively; and 0.46 for heart. (B) Total body weights before and after 7 weeks of the indicated concentration of dietary ursolic acid.
P values were 0.71 and 0.80 for initial and final weights, respectively.
(C–F) Mice were provided ad libitum access to either standard chow (control diet) or standard chow supplemented with 0.27% ursolic acid (ursolic acid diet) for
5 weeks, as in Figure 4. (C) Relationship between skeletal muscle weight (quadriceps, triceps, biceps, TA, gastrocnemius, and soleus) and retroperitoneal
adipose weight. Each data point represents onemouse. p < 0.001 for both muscle and adipose by unpaired t test. (D) Representative H&E stain of retroperitoneal
fat. (E) Effect of ursolic acid on average retroperitoneal adipocyte diameter. Each data point represents the average diameter ofR125 retroperitoneal adipocytes
from one mouse. (F) Effect of ursolic acid on retroperitoneal adipocyte size distribution. Each distribution represents combined adipocyte measurements (>1000
per diet) from (E).
(G and H) Mice were fed as in (A) and (B). (G) Plasma leptin. Each data point represents one mouse, and horizontal bars denote the means. P values were
determined by t test. (H) Relationship between adipose weight and plasma leptin. Each data point represents one mouse.
(I and J) Mice were fed as in (C)–(F) before plasma TGs (I) and cholesterol (J) were measured. Each data point represents one mouse, and horizontal bars denote
the means. P values were determined by unpaired t test. See also Figure S4.
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that ursolic acid-mediated IGF1 induction may be localized to
skeletal muscle.
Ursolic Acid Enhances Skeletal Muscle Insulin/IGF-I
Signaling
Althoughmuscle-specific IGF1 induction is characteristic of, and
contributes to, muscle hypertrophy, it may be a relatively late
event that promotes hypertrophy after it has been initiated by
other stimuli (Adams et al., 1999). We hypothesized that ursolic
acidmight have amore proximal effect on insulin/IGF-I signaling.
In a previous study of nonmuscle cell lines (CHO/IR and 3T3-L1
cells), ursolic acid enhanced insulin-mediated Akt activation
(Jung et al., 2007). To determine whether ursolic acid might
have a similar effect in skeletalmuscle,we first assessed the level
of phosphorylated Akt in quadriceps muscles of mice fed diets
lacking or containing ursolic acid. In quadriceps, ursolic acid
increased Akt phosphorylation by 1.8-fold (Figures 5D and 5E).
We next examined whether ursolic acid might increase Akt
activation in C2C12 skeletal myotubes, awell-established in vitro
model of skeletal muscle (Sandri et al., 2004; Stitt et al., 2004).
Use of an in vitro system circumvented potentially confounding
effects from nonmuscle tissues and allowed us to test if IGF-I
or insulin was required for ursolic acid’s effect. The latter consid-
eration was important because circulating IGF-I and insulin are
always present in healthy animals. Use of an in vitro system
also allowed us to test a clearly defined concentration of ursolic
acid (10 mM, similar what was used in the Connectivity Map
[8.8 mM]) for a clearly defined time of incubation (20 min). These
considerations were important because the in vivo pharmacoki-
netic properties of ursolic acid are not yet known. When
serum-starved myotubes were treated with ursolic acid alone,
Akt phosphorylation did not increase (Figure 5F). However, in
the presence of IGF-I, ursolic acid increased Akt phosphoryla-
tion by 1.9-fold (Figures 5F and 5I). Ursolic acid also increased
Akt phosphorylation in the presence of insulin (Figure S3).
Thus, ursolic acid enhanced IGF-I-mediated and insulin-medi-
ated Akt phosphorylation.
The finding that ursolic acid enhanced muscle Akt activity
in vivo and in vitro was consistent with the finding that ursolic
acid’s mRNA expression signature negatively correlated with
the mRNA expression signatures of LY-294002 and wortmannin
(Figures 2B and 3B), which inhibit insulin/IGF-I signaling
upstream of Akt. However, ursolic acid’s signature also nega-
tively correlated with the signature of rapamycin, which inhibits
insulin/IGF-I signaling downstream of Akt. We therefore asked
whether ursolic acid might enhance S6 kinase (S6K) phosphory-
lation, which occurs distal to the effect of rapamycin. Although
ursolic acid alone did not increase S6K phosphorylation (Fig-
ure S3), it enhanced IGF-I-mediated and insulin-mediated S6K
phosphorylation (Figures 5G and 5I and Figure S3).
To further investigate the mechanism, we examined the IGF-I
receptor. Ursolic acid increased IGF-I receptor phsophorylation
in the presence but not the absence of IGF-I (Figures 5H and 5I).
Similarly, ursolic acid increased insulin receptor phosphorylation
in the presence but not the absence of insulin (Figure S3). Both of
these effects were rapid, occurring within 2min after the addition
of ursolic acid and either IGF-I or insulin. Consistent with
enhanced signaling at the level of the IGF-I and insulin receptors,Cursolic acid also enhanced IGF-I-mediated and insulin-mediated
ERK phosphorylation (Figure 5J and Figure S3). Moreover,
ursolic acid enhanced IGF-I-mediated phosphorylation (inhibi-
tion) of FoxO transcription factors, which activate transcription
of atrogin-1 and MuRF1 mRNAs (Figure 5K; Sandri et al., 2004;
Stitt et al., 2004). Taken together, these data indicate that ursolic
acid represses atrophy-associated gene expression and pro-
motes muscle hypertrophy by increasing activity of the IGF-I
and insulin receptors.
In Contrast to Its Effect on Skeletal Muscle, Ursolic Acid
Reduces Adiposity
Figure 6A shows that 7 weeks of dietary ursolic acid increased
skeletal muscle weight in a dose-dependent manner, with a
peak effect at 0.14%. Interestingly, although ursolic acid in-
creased muscle weight, it did not increase total body weight
(Figure 6B). Because ursolic acid increasedAkt activity (Figure 5),
and because muscle-specific increases in Akt activity reduce
adiposity as a secondary consequence of muscle hypertrophy
(Izumiya et al., 2008; Lai et al., 2004), we hypothesized that
ursolic acid-treated mice might contain less fat. Indeed, 7 weeks
of dietary ursolic acid reduced the weight of epididymal and
retroperitoneal fat depots, with a peak effect at 0.14% (Fig-
ure 6A). Similar results were obtained when mice were fed
a diet containing 0.27% ursolic acid for 5 weeks (Figure 6C).
Thus, muscle and fat weights were inversely related.
Ursolic acid reduced adipose weight by reducing adipocyte
size (Figures 6D–6F). This was accompanied by a significant
reduction in plasma leptin levels, which correlated closely with
adipose weight (Figures 6G and H). Although ursolic acid
reduced leptin, it did not alter food intake (Figure S4). Impor-
tantly, ursolic acid also significantly reduced plasma TG
(Figure 6I) and cholesterol (Figure 6J). However, ursolic acid
did not alter weights of heart (Figure 6A), liver, or kidney (Fig-
ure S4), nor did it elevate plasma markers of hepatotoxicity or
nephrotoxicity (alanine aminotransferase, bilirubin, and creati-
nine) (Figure S4). Thus, dietary ursolic acid had twomajor effects:
skeletal muscle hypertrophy and reduced adiposity.
DISCUSSION
Landmark studies using rodent models showed that diverse
atrophy-inducing stresses (including fasting, systemic illness,
and muscle disuse) generate similar patterns of changes in skel-
etal mRNA expression (Sacheck et al., 2007). We translated
those findings to humans by determining the effect of fasting
on global skeletal muscle mRNA expression in human skeletal
muscle. Our fasting protocol waswell tolerated by subjects, rela-
tively simple to execute, and required only a few subjects to
discern important changes in skeletal muscle mRNA expression.
For example, it allowed us to demonstrate, for the first time,
fasting-mediated induction of atrogin-1 and MuRF1 mRNAs in
human skeletal muscle.
In human skeletal muscle, fasting altered levels of >500
skeletal muscle mRNAs (approximately 3% of the total mRNAs
examined). However, only a few of these mRNAs are known to
play central roles in muscle atrophy in mice (including atrogin-1,
MuRF1, ZFAND5, and PGC-1a). Likewise, most mRNAs that
were altered by fasting in both human and mouse muscle (whichell Metabolism 13, 627–638, June 8, 2011 ª2011 Elsevier Inc. 635
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mRNAs that were altered by both fasting and SCI in human
muscle (which formed the basis for our second Connectivity
Map query), have undefined roles in muscle atrophy. Although
we do not yet know the functional roles of most mRNAs whose
levels are altered by fasting or SCI, or the precise mechanisms
that regulate them in the setting of an atrophy-inducing stress,
we used these data to query the Connectivity Map. This unbi-
ased approach singled out one compound as a predicted inhib-
itor of atrophy-inducing stress: ursolic acid.
A water-insoluble pentacyclic triterpenoid, ursolic acid is the
major waxy component in apple peels (Frighetto et al., 2008). It
is also found in many other edible plants. Interestingly, because
it exerts beneficial effects in animal models of diabetes and
hyperlipidemia (Liu, 1995; Wang et al., 2009), ursolic acid is
thought to be the active component in a variety of folkloric anti-
diabetic herbal medicines (Liu, 1995, 2005). As predicted by the
Connectivity Map, we found that ursolic acid reduced skeletal
muscle atrophy in the setting of two distinct atrophy-inducing
stresses (fasting and muscle denervation). A major strength of
the Connectivity Map is that it takes into account positive and
negative changes in mRNA expression that together constitute
an authentic mRNA expression signature. Thus, by querying
the Connectivity Map with signatures of muscle atrophy, we
were, in effect, querying with the reciprocal signature of muscle
hypertrophy. Indeed, ursolic acid not only reduced muscle
atrophy but also induced muscle hypertrophy.
The strategy that led us to ursolic acid implied that ursolic acid
might increase muscle mass by inhibiting atrophy-associated
skeletal muscle gene expression. Indeed, we found that acute
ursolic acid treatment of fasted mice reduced atrogin-1 and
MuRF1 mRNAs in association with reduced muscle atrophy.
Similarly, chronic ursolic acid treatment of unstressed mice
reduced atrogin-1 and MuRF1 mRNAs and induced muscle
hypertrophy. Interestingly, ursolic acid-induced muscle hyper-
trophy was also associated with induction or repression of >60
other skeletal muscle mRNAs, including IGF1 mRNA (which
was induced). Although previous studies showed that increased
skeletal muscle IGF1 expression is sufficient to inhibit atrophy
and promote hypertrophy, we noted that, following a hypertro-
phic stimulus such as mechanical loading, increased IGF1
gene expression is a late event (Adams et al., 1999).We therefore
asked whether ursolic acid might stimulate earlier events in
insulin/IGF-I signaling by examining skeletal muscle Akt activa-
tion, a critical node in the insulin and IGF-I signaling cascades.
Indeed, in muscles that had hypertrophied secondary to chronic
ursolic acid treatment, Akt phosphorylation was increased.
Interestingly, this increase in skeletal muscle Akt activity can
potentially account for many of ursolic acid’s effects, including
reduced atrophy-associated gene expression, reduced muscle
atrophy, increased muscle hypertrophy, and reduced adiposity
(Izumiya et al., 2008; Lai et al., 2004). However, additional studies
will be needed to determine whether Akt is required for the
effects of ursolic acid, and whether other pathways (such as
the calcineurin/NFAT and MAP kinase pathways) might also be
involved.
Although ursolic acid increased skeletal muscle Akt phosphor-
ylation in vivo, those experiments could not determine if ursolic
acid acted directly on skeletal muscle, how quickly ursolic acid636 Cell Metabolism 13, 627–638, June 8, 2011 ª2011 Elsevier Inc.acted, and if the effect of ursolic acid required IGF-I or insulin,
which are always present in healthy animals, even during fasting.
To address these questions, we studied serum-starved skeletal
myotubes and found that ursolic acid rapidly stimulated IGF-I
receptor and insulin receptor activity, but only if IGF-I or insulin
was also present. Taken together, our data suggest that ursolic
acid first enhances the capacity of pre-existing IGF-I and insulin
to activate skeletal muscle IGF-I receptors and insulin receptors,
respectively. This activates Akt, S6K, and ERK and alters skeletal
muscle gene expression in a manner that reduces atrophy and
promotes hypertrophy. Specific changes in downstream gene
expression include induction of IGF1 (a feed-forwardmechanism
that likely contributes to ursolic acid-mediated hypertrophy),
repression of atrogin-1 andMuRF1, and induction or repression
of many other genes whose contributions to muscle atrophy or
hypertrophy remain to be determined. Some of these changes
in skeletal muscle gene expression (such as repression of
atrogin-1 and MuRF1) can be explained by our finding that
ursolic acid enhances IGF-I-mediated inhibition of FoxO tran-
scription factors. However, ursolic acid might also inhibit other
transcription factors that promote atrophy, such as NF-kB, and
this is an important area for future investigation.
Importantly, ursolic acid alone was not sufficient to increase
phosphorylation of the IGF-I receptor or the insulin receptor.
Rather, its effects also required IGF-I or insulin, respectively.
This suggests that ursolic acid either facilitates hormone-
mediated receptor autophosphorylation or it inhibits receptor
dephosphorylation. The latter possibility is supported by
previous in vitro data showing that ursolic acid directly inhibits
PTP1B (Zhang et al., 2006), a tyrosine phosphatase that dephos-
phorylates (inactivates) the IGF-I and insulin receptors (Kenner
et al., 1996). However, neither global nor muscle-specific
PTP1B knockout mice were found to possess increased muscle
mass (Delibegovic et al., 2007; Klaman et al., 2000). This may
suggest the existence of another receptor for ursolic acid, which
might be closely related to PTP1B. Identifying the receptor(s) for
ursolic acid is an important area for future investigation that may
elucidate important mechanisms of metabolic control. Pharma-
cokinetic studies of ursolic acid will also be critical for fully under-
standing its in vivo effects.
Given the current lack of therapies for skeletal muscle atrophy,
we speculate that ursolic acid might be investigated as a poten-
tial therapy for illness- and age-relatedmuscle atrophy. It may be
useful as a monotherapy or in combination with other strategies
that have been considered, such as myostatin inhibition
(Zhou et al., 2010). Given its capacity to reduce adiposity, fasting
blood glucose, and plasma lipid levels, ursolic acid might also be
investigated as a potential therapy for obesity, metabolic
syndrome, and type 2 diabetes. A systematic search for ursolic
acid derivatives that are more potent and/or efficacious could
also be undertaken. Further work in this area may lead to new
medical therapies for increasingly common metabolic diseases
that reduce the absolute or relative amount of skeletal muscle.EXPERIMENTAL PROCEDURES
Human Subjects
Our study was approved by the Institutional Review Board at the University of
Iowa and involved seven healthy adults who gave their informed consent
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Ursolic Acid Reduces Skeletal Muscle Atrophybefore participating. One week prior to the fasting study, subjects made one
visit to the CRU for anthropometric measurements, a dietary interview that
established each subject’s routine food intake and food preferences, and
baseline determinations of blood hemoglobin A1c (by turbidimetric immunoin-
hibition using the Hitachi 911 analyzer; Boehringer Mannheim, Indianapolis,
IN), plasma TGs, plasma free T4 and TSH (by electrochemiluminescence
immunoassay using the Elecsys system; Roche Diagnostics, Indianapolis,
IN), plasma CRP (by immunoturbidimetric assay; Roche Integra high-sensi-
tivity assay), and plasma TNF-a levels (by the Quantikine kit fromR&DSystems
Inc., Minneapolis, MN). To ensure that subjects were eating their routine diet
prior to the fasting study, subjects ate only meals prepared by the CRU dieti-
cian (based on the dietary interview) for 48 hr before the fasting study. The
fasting study began at t = 0 hr, when subjects were admitted to the CRU
and began fasting. While fasting, subjects remained in the CRU and were
encouraged to maintain their routine physical activities. Water was allowed
ad libitum, but caloric intake was not permitted. At t = 40 hr, a percutaneous
biopsy was taken from the VL muscle using a Temno biopsy needle (T1420,
CardinalHealth) under ultrasound guidance. Subjects then ate a CRU-
prepared mixed meal, and at t = 46 hr a muscle biopsy was taken from the
contralateral VL muscle. Plasma glucose and insulin levels were measured
at t = 36, 40, 42, and 46 hr; the Elecsys system was used to quantitate plasma
insulin. Our study protocol of humans with SCI was described previously
(Adams et al., 2011).
Mouse Protocols
Male C57BL/6 mice, ages 6–8 weeks, were obtained from NCI, housed in
colony cages with 12 hr light/12 hr dark cycles, and used for experiments
within 3 weeks of their arrival. Unless otherwise indicated, mice were main-
tained on standard chow (Harlan Teklad formula 7013). Metformin (Sigma)
was dissolved in 0.9% NaCl at a concentration of 25 mg/ml. Ursolic acid
(Enzo Life Sciences) was dissolved in corn oil at a concentration of 20 mg/ml
(for i.p. injections) or custom added to chow formula 7013 by Harlan Teklad.
Mice were fasted by removing food, but not water, for 24 hr. Fasting blood
glucose levels were obtained from the tail vein with an Accucheck Aviva
glucose meter. Unilateral hindlimb muscle denervation was performed by
transsecting the sciatic nerve under anesthesia, and was followed by admin-
istration of ursolic acid (200 mg/kg) or vehicle alone (corn oil) via i.p. injection
twice daily for 7 days. Forelimb grip strength was determined using a grip
strength meter equipped with a triangular pull bar (Columbus Instruments).
Each mouse was subjected to five consecutive tests to obtain the peak value.
Plasma IGF-I and leptin levels were measured by RIA at the Vanderbilt Univer-
sity Hormone Assay Core Facility. Plasma cholesterol, TG, creatinine, bilirubin,
and ALT were measured using the VITROS 350 Chemistry System. All animal
procedures were approved by the Institutional Animal Care and Use
Committee of the University of Iowa.
Microarray Analysis of Skeletal Muscle mRNA Levels
Following harvest, skeletal muscle samples were immediately placed in RNA-
later (Ambion) and stored at 80C until further use. Total RNA was extracted
using TRIzol solution (Invitrogen), and microarray hybridizations were per-
formed at the University of Iowa DNA Facility, as described previously
(Ebert et al., 2010). Our reported log2 hybridization signals reflect the mean
signal intensity of all exonprobes specific for an individualmRNA. Todetermine
which human skeletal muscle mRNAs were significantly altered by fasting
(p% 0.02), we used paired t tests to compare fasted and fed log2 signals. To
determine which mouse skeletal muscle mRNAs were significantly altered by
ursolic acid (p % 0.005), we used unpaired t tests to compare log2 signals in
mice fed control diet or diet supplemented with ursolic acid; then, to focus
on highly expressed mRNAs, we selected for significantly altered mRNAs
that were repressed from or induced to a log2 signal >8. Exon array studies
of the effects of fasting on mouse skeletal muscle, and the effects of SCI on
human skeletal muscle, were described previously (Adams et al., 2011; Ebert
et al., 2010).
Other Methods
Additional information on qPCR, histological, and immunoblot methods may
be found in the Supplemental Experimental Procedures.CACCESSION NUMBERS
The microarray data from humans and mice have been deposited in the NCBI
Gene Expression Omnibus under GEO Series accession numbers GSE28016
and GSE28017, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, four tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.03.020.
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